ID

12464

Beschreibung

The purpose of this study is to test the hypothesis that the onset of the antiplatelet effect of ticagrelor is more rapid and greater than clopidogrel in Chinese patients with ACS. https://clinicaltrials.gov/ct2/show/NCT01864005

Link

https://clinicaltrials.gov/ct2/show/NCT01864005

Stichworte

  1. 28.07.15 28.07.15 -
  2. 21.11.15 21.11.15 -
Hochgeladen am

21. November 2015

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility HouYi Acute Coronary Syndrome NCT01864005

Eligibility criteria

  1. StudyEvent: ODM
    1. Eligibility criteria
Inclusion Criteria
Beschreibung

Inclusion Criteria

Provision of informed consent prior to any study specific procedures
Beschreibung

Provision of informed consent prior to any study specific procedures

Datentyp

boolean

Alias
UMLS CUI-1
C0021430
Female or male
Beschreibung

Female or male

Datentyp

boolean

Alias
UMLS CUI-1
C0079399
Aged at least 18 years
Beschreibung

Aged at least 18 years

Datentyp

boolean

Alias
UMLS CUI-1
C0001779
Females of child-bearing potential must have a negative urine pregnancy test at enrolment
Beschreibung

Females of child-bearing potential must have a negative urine pregnancy test at enrolment

Datentyp

boolean

Alias
UMLS CUI-1
C0549206
Females of child-bearing potential must be willing to use reliable contraception
Beschreibung

Females of child-bearing potential must be willing to use reliable contraception

Datentyp

boolean

Alias
UMLS CUI-1
C0009871
Index event of non-ST or ST segment elevation ACS.
Beschreibung

Index event of non-ST or ST segment elevation ACS.

Datentyp

boolean

Alias
UMLS CUI [1]
C0948089
Exclusion Criteria
Beschreibung

Exclusion Criteria

Contraindication or other reason that clopidogrel should not be administered
Beschreibung

Contraindication or other reason that clopidogrel should not be administered

Datentyp

boolean

Alias
UMLS CUI-1
C1319916
Contraindication or other reason that ticagrelor should not be administered
Beschreibung

Contraindication or other reason that ticagrelor should not be administered

Datentyp

boolean

Alias
UMLS CUI-1
C1999375
UMLS CUI-2
C0522473
Oral anticoagulation therapy within 30 days prior to randomisation or cannot be stopped
Beschreibung

Oral anticoagulation therapy

Datentyp

boolean

Alias
UMLS CUI-1
C0354604
GP IIb/IIIa receptor antagonists therapy within 30 days prior to randomisation or cannot be stopped
Beschreibung

GP IIb/IIIa receptor antagonists therapy within 30 days prior to randomisation or cannot be stopped

Datentyp

boolean

Alias
UMLS CUI-1
C3640054
Ticagrelor within 14 days prior to randomisation
Beschreibung

Ticagrelor within 14 days prior to randomisation

Datentyp

boolean

Alias
UMLS CUI-1
C1999375
Clopidogrel within 14 days prior to randomisation
Beschreibung

Clopidogrel or other P2Y12 inhibitors within 14 days prior to randomisation

Datentyp

boolean

Alias
UMLS CUI-1
C0070166
P2Y12 inhibitors within 14 days prior to randomisation
Beschreibung

P2Y12 inhibitors within 14 days prior to randomisation

Datentyp

boolean

Alias
UMLS CUI-1
C2936588
Requires dialysis
Beschreibung

Requires dialysis

Datentyp

boolean

Alias
UMLS CUI-1
C0019004
Nonselective non-steroidal anti-inflammatory drugs therapy that cannot be stopped
Beschreibung

Nonselective non-steroidal anti-inflammatory drugs therapy that cannot be stopped

Datentyp

boolean

Alias
UMLS CUI-1
C0003211
prostacyclins (PGI2) therapy that cannot be stopped
Beschreibung

prostacyclins (PGI2) therapy that cannot be stopped

Datentyp

boolean

Alias
UMLS CUI-1
C2825061

Ähnliche Modelle

Eligibility criteria

  1. StudyEvent: ODM
    1. Eligibility criteria
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
Inclusion Criteria
Informed consent
Item
Provision of informed consent prior to any study specific procedures
boolean
C0021430 (UMLS CUI-1)
Gender
Item
Female or male
boolean
C0079399 (UMLS CUI-1)
Age
Item
Aged at least 18 years
boolean
C0001779 (UMLS CUI-1)
Pregnancy
Item
Females of child-bearing potential must have a negative urine pregnancy test at enrolment
boolean
C0549206 (UMLS CUI-1)
Contraceptive
Item
Females of child-bearing potential must be willing to use reliable contraception
boolean
C0009871 (UMLS CUI-1)
Acute coronary syndrome
Item
Index event of non-ST or ST segment elevation ACS.
boolean
C0948089 (UMLS CUI [1])
Item Group
Exclusion Criteria
Clopidogrel contraindicated
Item
Contraindication or other reason that clopidogrel should not be administered
boolean
C1319916 (UMLS CUI-1)
Ticagrelor contraindicated
Item
Contraindication or other reason that ticagrelor should not be administered
boolean
C1999375 (UMLS CUI-1)
C0522473 (UMLS CUI-2)
Oral anticoagulants
Item
Oral anticoagulation therapy within 30 days prior to randomisation or cannot be stopped
boolean
C0354604 (UMLS CUI-1)
GPIIb/IIIa receptor antagonist
Item
GP IIb/IIIa receptor antagonists therapy within 30 days prior to randomisation or cannot be stopped
boolean
C3640054 (UMLS CUI-1)
Ticagrelor
Item
Ticagrelor within 14 days prior to randomisation
boolean
C1999375 (UMLS CUI-1)
Clopidogrel
Item
Clopidogrel within 14 days prior to randomisation
boolean
C0070166 (UMLS CUI-1)
Thienopyridines
Item
P2Y12 inhibitors within 14 days prior to randomisation
boolean
C2936588 (UMLS CUI-1)
Hemodialysis
Item
Requires dialysis
boolean
C0019004 (UMLS CUI-1)
NSAID
Item
Nonselective non-steroidal anti-inflammatory drugs therapy that cannot be stopped
boolean
C0003211 (UMLS CUI-1)
Prostacycline
Item
prostacyclins (PGI2) therapy that cannot be stopped
boolean
C2825061 (UMLS CUI-1)

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video